Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
Standalone profit from operations for the quarter were Rs. 162 crores
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
